Author

A. Casimiro-Garcia

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biophysics· 1 Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:rat· 1

Frequent Co-Authors

F. Wang· 2 shared A. Dong· 1 shared A. Giddabasappa· 1 shared A. K. Yazdi· 1 shared A. Pinto-Fernandez· 1 shared B. G. Johnson· 1 shared B. M. Kessler· 1 shared B. Yang· 1 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiophysics

F. Wang

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Chemical Tools for the Gid4 Subunit of the Human E3 Ligase C-terminal to LisH (CTLH) Degradation Complex

A. K. Yazdi, S. Perveen, X. Song, A. Dong, M. Szewczyk, M. Calabrese, A. Casimiro-Garcia, C. Subramanyam, M. S. Dowling, E. Ficici, J. Lee, J. I. Montgomery, T. N. O'Connell, G. J. Skrzypek, T. P. Tran, , D. R. Owen

The paper develops chemical tools and probes for the Gid4 subunit of the human CTLH E3 ligase complex, achieving sub-100 nM binding affinity for further study.

bioRxiv · Nov 13, 2023Biophysics

Human USP18 protects diverse cancer lineages from Type I Interferon independently of its canonical catalytic function

V. Jove, H. Wheeler, C. W. Lee, D. R. Healy, K. Levine, E. C. Ralph, B. Yang, A. Giddabasappa, P. Loria, M. Yamaguchi, A. Casimiro-Garcia, B. M. Kessler, A. Pinto-Fernandez, V. Frattini, P. D. Wes, F. Wang

This paper shows USP18's scaffold function, not its catalytic activity, is critical for inhibiting cancer growth and Type I interferon signaling in human cells.

bioRxiv · Mar 23, 2023 · PreprintCancer Biology

Pharmacologic inhibition of Protein Kinase C α and Protein Kinase C β halts renal function decline indirectly, by blunting hyperphagia, and directly reduces adiposity in the ZSF1 rat model of type 2 diabetes

J. Wang, A. Casimiro-Garcia, B. G. Johnson, J. Duffen, M. Cain, L. Savary, S. Wang, P. Nambiar, M. Lech, S. Zhao, L. Xi, Y. Zhan, J. Olson, J. A. Stejskal, H. Lin, , K. Dower

The paper evaluates a PKC inhibitor in a T2D rat model, finding it halts renal decline indirectly via reduced hyperphagia and directly lowers adiposity.

bioRxiv · Dec 2, 2020 · PreprintPharmacology & Toxicology